Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT).

Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J.

Lung Cancer. 2010 Jul;69(1):77-85. doi: 10.1016/j.lungcan.2009.09.006. Epub 2009 Nov 11.

PMID:
19910075
2.

CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?

Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y, Wadasaki K, Hirokawa Y, Ito K, Okawa M.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):483-91. Epub 2006 Aug 14.

PMID:
16904838
3.

Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System.

Raziee H, Hope A, Faruqi S, Yap ML, Roberts H, Kandel S, Le LW, Brade A, Cho J, Sun A, Bezjak A, Giuliani ME.

Clin Lung Cancer. 2015 Nov;16(6):e245-51. doi: 10.1016/j.cllc.2015.05.008. Epub 2015 Jun 2.

PMID:
26077096
4.

Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors.

Matsuo Y, Nagata Y, Mizowaki T, Takayama K, Sakamoto T, Sakamoto M, Norihisa Y, Hiraoka M.

Int J Clin Oncol. 2007 Oct;12(5):356-62. Epub 2007 Oct 22.

PMID:
17929117
5.

Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors.

Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1024-30. doi: 10.1016/j.ijrobp.2011.11.080. Epub 2012 May 12.

PMID:
22583607
6.

Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy.

Kishan AU, Wang PC, Sheng K, Yu V, Ruan D, Cao M, Tenn S, Low DA, Lee P.

Technol Cancer Res Treat. 2015 Aug;14(4):411-8. doi: 10.1177/1533034614551476. Epub 2014 Sep 26.

PMID:
25261069
7.

Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Arcangeli S, Agolli L, Portalone L, Migliorino MR, Lopergolo MG, Monaco A, Dognini J, Pressello MC, Bracci S, Donato V.

Br J Radiol. 2015 Apr;88(1048):20140728. doi: 10.1259/bjr.20140728. Epub 2015 Feb 3.

8.

Repeat stereotactic body radiation therapy for patients with pulmonary malignancies who had previously received SBRT to the same or an adjacent tumor site.

Valakh V, Miyamoto C, Micaily B, Chan P, Neicu T, Li S.

J Cancer Res Ther. 2013 Oct-Dec;9(4):680-5. doi: 10.4103/0973-1482.126481.

9.

Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity.

Yoshida Y, Kokubu A, Suzuki K, Kuribayashi H, Tsuta K, Matsuno Y, Kusumoto M, Kanai Y, Asamura H, Hirohashi S, Shibata T.

Jpn J Clin Oncol. 2007 Dec;37(12):907-12. Epub 2007 Dec 18.

PMID:
18089646
10.

Dose impact in radiographic lung injury following lung SBRT: Statistical analysis and geometric interpretation.

Yu V, Kishan AU, Cao M, Low D, Lee P, Ruan D.

Med Phys. 2014 Mar;41(3):031701. doi: 10.1118/1.4863483.

PMID:
24593705
11.

Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.

Jeppesen SS, Schytte T, Jensen HR, Brink C, Hansen O.

Acta Oncol. 2013 Oct;52(7):1552-8. doi: 10.3109/0284186X.2013.813635. Epub 2013 Aug 1.

PMID:
23902274
12.

No differences in radiological changes after 3D Conformal vs. VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer.

Badellino S, Di Muzio J, Schivazappa G, Guarneri A, Ragona R, Bartoncini S, Trino E, Filippi AR, Fonio P, Ricardi U.

Br J Radiol. 2017 Jul 27:20170143. doi: 10.1259/bjr.20170143. [Epub ahead of print]

PMID:
28749172
13.

Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.

Matsuo Y, Shibuya K, Nagata Y, Norihisa Y, Narabayashi M, Sakanaka K, Ueki N, Mizowaki T, Hiraoka M.

J Thorac Oncol. 2012 Feb;7(2):453-6. doi: 10.1097/JTO.0b013e31823c5b29.

14.

Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).

Stephans KL, Djemil T, Tendulkar RD, Robinson CG, Reddy CA, Videtic GM.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):974-80. doi: 10.1016/j.ijrobp.2010.12.002. Epub 2011 Feb 6.

PMID:
21300453
15.

Radiological changes after stereotactic radiotherapy for stage I lung cancer.

Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S.

J Thorac Oncol. 2011 Jul;6(7):1221-8. doi: 10.1097/JTO.0b013e318219aac5. Erratum in: J Thorac Oncol. 2011 Sep;6(9):1616.

16.

Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor.

Ochiai S, Nomoto Y, Yamashita Y, Murashima S, Hasegawa D, Kurobe Y, Toyomasu Y, Kawamura T, Takada A, Ii N.

J Radiat Res. 2015 Nov;56(6):904-11. doi: 10.1093/jrr/rrv049. Epub 2015 Sep 2.

17.

Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance.

Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, Oya N, Mitsumori M, Hiraoka M.

Radiology. 2004 Jan;230(1):101-8. Epub 2003 Nov 26.

PMID:
14645881
18.

Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes.

Linda A, Trovo M, Bradley JD.

Eur J Radiol. 2011 Jul;79(1):147-54. doi: 10.1016/j.ejrad.2009.10.029. Epub 2009 Dec 1. Review.

PMID:
19954913
19.

Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: long-term follow-up of radiological findings.

Soda H, Nakamura Y, Nakatomi K, Tomonaga N, Yamaguchi H, Nakano H, Nagashima S, Anami M, Hayashi T, Tsukamoto K, Kohno S.

Lung Cancer. 2008 May;60(2):298-301. Epub 2007 Oct 24.

PMID:
17928095
20.

Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung.

Matsuguma H, Nakahara R, Anraku M, Kondo T, Tsuura Y, Kamiyama Y, Mori K, Yokoi K.

Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6.

PMID:
15145016

Supplemental Content

Support Center